<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The immune reactivity of allogeneic lymphocytes plays a major role in the control of <z:hpo ids='HP_0001909'>leukemia</z:hpo> after bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with recurrent <z:hpo ids='HP_0001909'>leukemia</z:hpo> after marrow transplantation, chimerism and tolerance provide ideal conditions for adoptive immunotherapy with donor lymphocytes </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the effect of donor lymphocyte transfusions on <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0005558'>chronic leukemia</z:hpo> in relapse after bone marrow transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred thirty-five patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (N = 84), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (N = 23), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (N = 22), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (N = 5), and <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera with <z:e sem="disease" ids="C0948968" disease_type="Disease or Syndrome" abbrv="">osteomyelofibrosis</z:e> (PCV) (N = 1) were treated with transfusions of donor lymphocytes </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were monitored for response of <z:hpo ids='HP_0001909'>leukemia</z:hpo>, including in <z:mp ids='MP_0005481'>CML</z:mp>, the use of the polymerase chain reaction for bcr/abl <z:chebi fb="2" ids="33699">mRNA</z:chebi> transcripts and for the occurrence of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Complete remissions were induced by donor lymphocyte transfusions in 54 patients with <z:mp ids='MP_0005481'>CML</z:mp> (73%) and in the patient with PCV; complete remissions were also induced in five patients (29%) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, ALL did not respond to adoptive immunotherapy with donor lymphocyte transfusions </plain></SENT>
<SENT sid="7" pm="."><plain>Remissions were durable in patients treated for <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (probability of remission: 87% at 3 years) </plain></SENT>
<SENT sid="8" pm="."><plain>Lymphocyte transfusions were also given to 18 patients with ALL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and transformed phase <z:mp ids='MP_0005481'>CML</z:mp> who were in remission after chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>These remissions were not durable </plain></SENT>
<SENT sid="10" pm="."><plain>Fifty-two patients (41%) developed GVHD of grade 2 or more, and 41 patients (34%) showed signs of <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Seventeen patients died without <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 14 patients with GVHD and/or <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Donor lymphocyte transfusions exert strong effects against myeloid forms of <z:hpo ids='HP_0001909'>leukemia</z:hpo> and induce durable remissions in <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
</text></document>